A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks
NCT00719914 is a phase 2 interventional trial sponsored by Brigham and Women's Hospital. As of 21 Nov 2026, it was terminated. It studies Eptifibatide and Normal saline in ST-Elevation Myocardial Infarction. The registry lists an enrollment of 31 participants at 3 sites in 1 country. The registry lists a start date of 30 Nov 2007 and a primary completion date of 30 Nov 2008.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00719914 |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Brigham and Women's Hospital |
| Enrollment | 31 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | ST-Elevation Myocardial Infarction |
| Drugs | Eptifibatide and Normal saline |
| Start | 30 Nov 2007 |
| Primary completion | 30 Nov 2008 |
| Study completion | 31 Jan 2009 |
| Last update posted | 27 Aug 2012 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- C. Michael Gibson, M.D.
The TIMI Study Group
Principal Investigator - Eugene Braunwald, M.D.
The TIMI Study Group
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cardiology Research Associates
Ormond Beach
- Crittenton Hospital Medical Center
Rochester
- Mid Ohio Heart Clinic
Mansfield
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00719914
Each answer restates registry values shown on this page.
What is NCT00719914?
NCT00719914 is a phase 2 interventional trial sponsored by Brigham and Women's Hospital. It studies Eptifibatide and Normal saline in ST-Elevation Myocardial Infarction.
Who leads NCT00719914?
The registry names C. Michael Gibson, M.D. (principal investigator, The TIMI Study Group) and Eugene Braunwald, M.D. (study chair, The TIMI Study Group) as overall officials.
Where does NCT00719914 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00719914 study?
The registered drug and biological interventions are Eptifibatide and Normal saline.
When did NCT00719914 end?
The registry lists a primary completion date of 30 Nov 2008 and a study completion date of 31 Jan 2009. The sponsor last updated the record on 27 Aug 2012.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.